within Pharmacolibrary.Drugs.V_Various.V09I_TumourDetection.V09IX01_Iobenguane123i;

model Iobenguane123i
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 3.3055555555555558e-06,
    adminDuration = 600,
    adminMass = 370 / 1000000,
    adminCount = 1,
    Vd = 0.0045,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.011800000000000001,
    k12 = 1.4194444444444443e-05,
    k21 = 1.4194444444444443e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Iobenguane123i</td></tr><tr><td>ATC code:</td><td>V09IX01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>370</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>4.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.17</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Iobenguane (123I), also known as 123I-metaiodobenzylguanidine or 123I-MIBG, is a radiopharmaceutical used for diagnostic imaging of neuroendocrine tumors such as pheochromocytoma and neuroblastoma. It is labeled with radioactive iodine-123, and is currently approved and used in nuclear medicine imaging.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients undergoing diagnostic imaging for neuroendocrine tumors.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V09IX01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Iobenguane123i;
